La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Dingdong (Cayman) a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Dingdong (Cayman)..

Dingdong (Cayman) (NYSE:DDL) Azioni, Catena delle Opzioni

Dingdong (Cayman)

Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Dingdong (Cayman) Ltd

WisdomTree Dynamic International SmallCap Equity Fund

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.64% on an annualized basis producing an average annual return of 14.78%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.92 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,844.79 today based on a price of $227.13 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746631889_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth Today

WIIM

Vishay Intertechnology shares are trading lower after the company reported worse-than-expected Q1 sales results.

DVAX

Dynavax Technologies shares are trading lower after the company reported worse-than-expected Q1 financial results.

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) is set to report its first-quarter financial results after Wednesday's closing bell. Here's a look at what to <a href="https://www.benzinga.com/general/sports/25/05/45180070/kentucky-derby-2025-how-to-watch-betting-odds-and-horses-backed-by-dutch-bros-founder-john-malone-george-soros">expect in the print. </a>
What To Watch: Wall Street will be watching to see if the drive-thru coffee chain can maintain the remarkable growth reported in previous quarters.
Analysts expect Dutch Bros to deliver revenue of approximately $344 million, reflecting 25% year-over-year growth, which is a slowdown compared to the 39.5% growth seen in the same quarter last year.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
However, foot-traffic <a href="https://www.placer.ai/anchor/articles/dutch-bros-gains-but-starbucks-holds-top-spot">data from </a>Placer.ai shows Dutch Bros' first-quarter visits were up 13.4% year-over-year, which could point to the potential for significant revenue increases. 
Company executives <a href="https://www.benzinga.com/25/02/43676849/dutch-bros-stock-rallies-after-blockbuster-q4-results-details">previously guided </a>fiscal 2025 revenue to be between $1.55 billion and $1.57 billion, which could also indicate a large beat of the consensus revenue estimate. 
Expert Ideas: Dutch Bros stock has a consensus price target of $70.06 based on the ratings of 18 analysts, according to <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">data from</a> Benzinga Edge. Wedbush issued a high of $90 on March 31, representing a 48% potential upside from current levels. 
Analysts expect the company to report quarterly earnings of 11 cents per share on revenue of $344.67 million. Dutch Bros has beaten top and bottom-line consensus estimates in each of the last six quarters. 
Dutch Bros stock has had volatile reactions to earnings releases in the past, with the stock price jumping more than 25% in after-hours trading following the company's fourth-quarter release.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45239803/sarepta-therapeutics-stock-plummets-after-q1-results-heres-why?utm_source=articleShare">Sarepta Therapeutics Stock Plummets After Q1 Results: Here&#8217;s Why&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Previews

Restaurants

General

BROS

Dutch Bros Q1 Earnings Preview: Will 13% Foot-Traffic Growth Lead To Another Blockbuster Quarter?

Keybanc analyst Jeffrey Hammond maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Overweight and raises the price target from $70 to $80.

Price Target

Analyst Ratings

ATKR

Keybanc Maintains Overweight on Atkore, Raises Price Target to $80

TRIP

TripAdvisor shares are trading higher after the company reported better-than-expected Q1 financial results.

Barrington Research analyst Kevin Steinke maintains Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) with a Outperform and lowers the price target from $44 to $39.

DSGR

Barrington Research Maintains Outperform on Distribution Solns Gr, Lowers Price Target to $39

Chemours shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, UBS lowered its price target on the stock from $18 to $17.

Cencora shares are trading higher after the company reported better-than-expected Q2 results and raised its FY25 adjusted EPS guidance.

Macquarie analyst Steve Koenig maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and lowers the price target from $175 to $140.

DDOG

Macquarie Maintains Outperform on Datadog, Lowers Price Target to $140

Greenfire Resources shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

<a href="https://www.youtube.com/watch?v=V2fIB2wx_i8" title="https://www.youtube.com/watch?v=V2fIB2wx_i8">https://www.youtube.com/watch?v=V2fIB2wx_i8</a>

Macro Economic Events

Economics

Treasury's Secretary Scott Bessent Says Many Bank Capital Regulations May Be 'Too Tight'

Goldman Sachs analyst George Tong maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Buy and lowers the price target from $622 to $535.

Goldman Sachs Maintains Buy on Gartner, Lowers Price Target to $535

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand shares are trading lower after the company reported mixed Q1 financial results and cut its FY25 adjusted EPS guidance below estimates. Also, Loop Capital lowered its price target on the stock from $16 to $15.

Guggenheim analyst Debjit Chattopadhyay maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and lowers the price target from $195 to $189.

KRYS

Guggenheim Maintains Buy on Krystal Biotech, Lowers Price Target to $189

SHOO

Steven Madden shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results

Goldman Sachs analyst Kate McShane maintains Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>) with a Neutral and raises the price target from $16 to $20.

DRVN

Goldman Sachs Maintains Neutral on Driven Brands Hldgs, Raises Price Target to $20

Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and lowers the price target from $78 to $55.

BEAM

Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $55

<ul>
<li>Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy</li>
<li>66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8</li>
<li>45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8</li>
<li>Efficacy and safety results were consistent with Phase 2 results of ZORYVE foam 0.3% in adults and adolescents 12 years of age and older</li>
<li>Supplemental New Drug Application (sNDA) for investigational ZORYVE foam 0.3% for psoriasis is under review with U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of May 22, 2025</li>
<li>More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement</li>
</ul>
WESTLAKE VILLAGE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of American Medical Association (JAMA) Dermatology <a href="https://www.globenewswire.com/Tracker?data=1wXVfiaShtAqtWU6oQjpU-q8_kJsanv2J_FXybY6C73fW5irU2O35PvfLlOdYDkxQA7zruMq1VanLx2NwRDldD_IKYm8C_c-d9hKD8fFygkKKxxs6SLytxZcy33QPXhX0biZKb827-TWKOvR6WSf6w==">published </a>the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE&#xAE; (roflumilast)&nbsp;foam 0.3% as a once-daily monotherapy treatment for psoriasis of the scalp and body.
The study showed that treatment with investigational ZORYVE foam resulted in significant improvements across multiple efficacy endpoints, including the co-primary efficacy endpoints of S-IGA Success and B-IGA Success, as well as key secondary endpoints. The data also show improvement in pruritus (itch) was observed as early as 24 hours after the first application.

ARQT

Arcutis Biotherapeutics Publishes Results From Pivotal Phase 3 Study Evaluating Efficacy And Safety Of ZORYVE Foam 0.3% As Once-daily Monotherapy Treatment For Psoriasis In JAMA Dermatology

CLOV

Clover Health Investments shares are trading higher. The company reported Q1 financial results.

Press Releases

Dingdong (Cayman) Limited Announces First Quarter 2024 Financial Results

Dingdong to Report Second Quarter 2024 Financial Results on August 7, 2024

Dingdong (Cayman) Limited Announces Second Quarter 2024 Financial Results

Dingdong to Report Third Quarter 2024 Financial Results on November 6, 2024

Dingdong (Cayman) Limited Announces Third Quarter 2024 Financial Results

Dingdong to Report Fourth Quarter 2024 Financial Results on March 6, 2025

Dingdong Announces US$20.0 Million Share Repurchase Program

Dingdong (Cayman) Limited Announces Fourth Quarter 2024 Financial Results

Dingdong Files Its Annual Report on Form 20-F

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

Chanson International Holding - Class A Ordinary Shares

Chanson International

Grocery Outlet Holding Corp. - Common Stock

Grocery Outlet Holding

Ingles Markets, Incorporated - Class A Common Stock

Ingles Markets

Kroger

Maison Solutions Inc. - Class A Common Stock

Maison Solutions

Natural Grocers by Vitamin Cottage, Inc. Common Stock

Natural Grocers

Reborn Coffee

Sprouts Farmers Market, Inc. - Common Stock

Sprouts Farmers Market

BBB Foods

Village Super Market, Inc. - Class A Common Stock

Village Super Market

Weis Markets

Meiwu Technology Company Limited - Ordinary Shares

Comments

Dingdong (Cayman)

Dingdong (Cayman) (DDL) Opzioni

Dingdong (Cayman) (NYSE:DDL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO